Pamela Stephenson - 27 Dec 2022 Form 4/A - Amendment Insider Report for ALBIREO PHARMA, INC.

Role: Chief Commercial Officer
Signature: /s/ Jason Duncan, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 27 Dec 2022
Net transactions value: -$8,940
Form type: 4/A - Amendment
Filing time: 09 Jan 2023, 17:42:08 UTC
Date Of Original Report: 27 Dec 2022
Previous filing: 25 Oct 2022
Next filing: 27 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALBO	Common Stock	Sale	$8,940	-469	-1%	$19.06	44,631	27 Dec 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2	Represents 18,374 shares of common stock and 26,257 restricted stock units.

Remarks:

This amended Form 4 is being filed solely to correct the numbers of shares disclosed in column 5 of Table I and footnote 3, as the reporting person did not acquire 547 shares of common stock under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022.